Oncotarget

Clinical Research Papers:

Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer

Francesca Galdiero _, Annunciata Romano, Rosa Pasquinelli, Sandro Pignata, Stefano Greggi, Emilia Vuttariello, Anna Maria Bello, Celeste Calise, Cono Scaffa, Carmela Pisano, Nunzia Simona Losito, Alfredo Fusco, Daniela Califano and Gennaro Chiappetta

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:19328-19335. https://doi.org/10.18632/oncotarget.2896

Metrics: PDF 1231 views  |   HTML 1466 views  |   ?  


Abstract

Francesca Galdiero1,*, Annunciata Romano1,*, Rosa Pasquinelli1, Sandro Pignata2, Stefano Greggi2, Emilia Vuttariello1, Anna Maria Bello1, Celeste Calise1, Cono Scaffa2, Carmela Pisano2, Nunzia Simona Losito3, Alfredo Fusco4, Daniela Califano1, Gennaro Chiappetta1

1Genomica Funzionale, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale”, IRCCS, Naples, Italy

2Dipartimento di Oncologia Uroginecologica, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale”, IRCCS, Naples, Italy

3Anatomia Patologica, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale”, IRCCS, Naples, Italy

4Istituto di Endocrinologia ed Oncologia Sperimentale - CNR Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Naples, Italy

*These authors have contributed equally to this work

Correspondence to:

Daniela Califano, e-mail: d.califano@istitutotumori.na.it

Keywords: Ovarian Cancer, HMGA2, plasma, circulating RNA

Received: July 25, 2014     Accepted: December 15, 2014     Published: February 12, 2015

ABSTRACT

Ovarian cancer is the most lethal gynecological malignancy and the high mortality rate is associated with advanced-stage disease at the time of the diagnosis. In order to find new tools to make diagnosis of Epithelial Ovarian Cancer (EOC) at early stages we have analyzed the presence of specific HMGA2 mRNA in the plasma of patients affected by this neoplasm. HMGA2 overexpression represents a feature of several malignances including ovarian carcinomas. Notably, we detected HMGA2 specific mRNA in the plasma of 40 out 47 patients with EOC, but not in the plasma of healthy donors. All cases found positive for HMGA2 mRNA in the plasma showed HMGA2 protein expression in EOC tissues.

Therefore, on the basis of these results, the analysis of circulating HMGA2 specific mRNA might be considered a very promising tool for the early diagnosis of EOC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2896